Scholarlink

Introduction <p>Heart failure (HF) is a major cause of hospitalization and mortality. Early initiation of guideline-directed medical therapy (GDMT) improves outcomes in heart failure with reduced ejection fraction (HFrEF). This study assesses the impact of starting GDMT with an SGLT2i in newly diagnosed HFrEF patients.</p> Materials and methods <p>The TIDY-HF multicenter prospective registry enrolled consecutive newly diagnosed HFrEF patients between October 2021 and March 2022 to evaluate the influence of medical treatment schedules in newly diagnosed HFrEF. In this substudy, patients were grouped by initial GDMT with or without an SGLT2i. Over six months, clinical variables, echocardiographic and laboratory parameters, and clinical events (hospitalizations, emergency visits) were collected. The primary aim was to compare GDMT implementation (quadruple therapy rates), with secondary aims assessing efficacy (target doses) and safety (adverse events).</p> Results <p>Of 518 patients, 400 initiated treatment with an SGLT2i, while 118 did not, with no differences in the baseline characteristics. At six months, 81.5% of patients who started with an SGLT2i were on quadruple therapy, compared to 61.2% in the non-SGLT2i group (<i>p</i> = 0.0001). The group starting with an SGLT2i showed a significant increase in left ventricular ejection fraction at 3&#xa0;months (14.2% vs 10.6%; <i>p</i> = 0.023) and preservation of renal function (GFR change: -4.7 vs + 0.4&#xa0;mL/min; <i>p</i> = 0.011). Furthermore, patients who started on SGLT2i showed a trend toward fewer HF decompensations and a significantly lower rate of non-cardiovascular hospitalizations.</p> Conclusions <p>Initiating GDMT with an SGLT2i facilitates the early implementation of quadruple therapy, improves LVEF, preserves renal function, and shows a trend toward reducing HF decompensations. SGLT2i initiation also demonstrated a favourable safety profile, supporting their early use in newly diagnosed HFrEF patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early initiation of SGLT2 inhibitors within guideline-directed medical therapy and outcomes in newly diagnosed heart failure patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月29日

查看全文
  • Alberto Esteban-Fernández,
  • Silvia López-Fernández,
  • Francisco J. Pastor-Pérez,
  • José Ángel Pérez-Rivera,
  • Juan Luis Bonilla-Palomas,
  • Marta Cobo-Marcos,
  • José Manuel García-Pinilla,
  • Luis Almenar-Bonet,
  • Paula Fluviá-Brugués,
  • Francisco J. Bermúdez-Jiménez,
  • Cristina Goena-Vives,
  • Andrea López-López,
  • Inés Gómez‑Otero,
  • Miguel Rodríguez-Santamarta,
  • Xabier Arana-Achaga,
  • Concepción Cruzado-Álvarez,
  • Inmaculada Fernández-Rozas,
  • Aleix Fort,
  • Belén Garcia,
  • Clara Jiménez-Rubio,
  • Laura Jordán-Martinez,
  • Bernardo Lanza-Reynolds,
  • Juan carlos Vázquez López-Ibor,
  • Ainara Lozano-Bahamonde,
  • Irene Marco-Clement,
  • Elisabet Mena-Sabastia,
  • Pedro Agustín Pájaro-Merino,
  • Alejandro Pérez-Cabeza,
  • Montserrat Puga-Martinez,
  • Ainhoa Robles-Mezcua,
  • Ester Sánchez-Corral,
  • Enrique Sánchez-Munoz,
  • José María Segura-Aumente,
  • Estefania Torrecilla,
  • Inaki Villanueva-Benito,
  • Virgilio Martínez-Mateo,
  • Javier Torres,
  • Vanesa Alonso-Fernández,
  • Javier de Juan Bagudá,
  • José Ignacio Morgado de Polavieja,
  • Itziar Solla‑Ruiz,
  • Eduard Solé‑González,
  • Montserrat Cardona,
  • Javier Rekondo-Olaetxea,
  • Carolina Ortiz-Cortés,
  • Victor Martínez-Dosantos,
  • Antonio Gámez-López,
  • Elvis Amao,
  • Borja Casas-Sánchez,
  • Edgardo Alania-Torres,
  • Víctor Gómez-Carrillo,
  • Daniel Garcia-Fuertes,
  • Francisco Ridocci‑Soriano,
  • Alba Maestro-Benedicto,
  • Sara Corredera-García

摘要

Introduction

Heart failure (HF) is a major cause of hospitalization and mortality. Early initiation of guideline-directed medical therapy (GDMT) improves outcomes in heart failure with reduced ejection fraction (HFrEF). This study assesses the impact of starting GDMT with an SGLT2i in newly diagnosed HFrEF patients.

Materials and methods

The TIDY-HF multicenter prospective registry enrolled consecutive newly diagnosed HFrEF patients between October 2021 and March 2022 to evaluate the influence of medical treatment schedules in newly diagnosed HFrEF. In this substudy, patients were grouped by initial GDMT with or without an SGLT2i. Over six months, clinical variables, echocardiographic and laboratory parameters, and clinical events (hospitalizations, emergency visits) were collected. The primary aim was to compare GDMT implementation (quadruple therapy rates), with secondary aims assessing efficacy (target doses) and safety (adverse events).

Results

Of 518 patients, 400 initiated treatment with an SGLT2i, while 118 did not, with no differences in the baseline characteristics. At six months, 81.5% of patients who started with an SGLT2i were on quadruple therapy, compared to 61.2% in the non-SGLT2i group (p = 0.0001). The group starting with an SGLT2i showed a significant increase in left ventricular ejection fraction at 3 months (14.2% vs 10.6%; p = 0.023) and preservation of renal function (GFR change: -4.7 vs + 0.4 mL/min; p = 0.011). Furthermore, patients who started on SGLT2i showed a trend toward fewer HF decompensations and a significantly lower rate of non-cardiovascular hospitalizations.

Conclusions

Initiating GDMT with an SGLT2i facilitates the early implementation of quadruple therapy, improves LVEF, preserves renal function, and shows a trend toward reducing HF decompensations. SGLT2i initiation also demonstrated a favourable safety profile, supporting their early use in newly diagnosed HFrEF patients.